NIH PAR · NIDA · R21

PAR-25-101: Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)

Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards

Open for applicationsNext due date: Mar 10, 2027Expires Aug 12, 2027

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant…

Full NOFO in the NIH Guide Apply on Grants.gov

NOFO number
PAR-25-101
Type
PAR
Activity code
R21
Primary institute
NIDA · National Institute on Drug Abuse
Clinical trials
Optional
Posted
Dec 30, 2024
Opens
Feb 10, 2025
Expires
Aug 12, 2027

PAR-25-101 due dates

2 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.

Application due dates and review cycles for PAR-25-101
Application Due Date(s)Renewal / Resubmission / Revision (as allowed)AIDS - New/Renewal/Resubmission/Revision, as allowedScientific Merit ReviewAdvisory Council ReviewEarliest Start Date
March 10, 2025March 10, 2025March 10, 2025July 2025October 2025December 2025
August 12, 2025August 12, 2025August 12, 2025November 2025January 2026April 2026
March 10, 2026March 10, 2026March 10, 2026July 2026October 2026December 2026
August 05, 2026August 05, 2026Not ApplicableNovember 2026January 2027April 2027
March 10, 2027March 10, 2027Not ApplicableJuly 2027October 2027December 2027
August 11, 2027August 11, 2027Not ApplicableNovember 2027January 2028April 2028

Projects funded under PAR-25-101

NIH RePORTER lists 2 projects funded under PAR-25-101 in FY2022–FY2026, with $696K in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.

Projects funded

2

Distinct projects, FY2022–FY2026

New awards

2

Type 1 (new project) award records

NIH funding

$696K

Award dollars under PAR-25-101, FY2022–FY2026

Funding by fiscal year

Award records, new awards, and funding by fiscal year under PAR-25-101
Fiscal yearAward recordsNew awardsFunding
FY202200$0
FY202300$0
FY202400$0
FY202500$0
FY202622$696K

Institutions with the most funding

Funding institutes

  • NIDA$696K · 2

Activity codes funded

What its predecessor PAR-21-208 funded

PAR-25-101 reissues PAR-21-208. Its funding history is the best guide to who wins under this program: 20 projects and $8.1M in FY2022–FY2026.

Projects funded

20

Distinct projects, FY2022–FY2026

New awards

20

Type 1 (new project) award records

NIH funding

$8.1M

Award dollars under PAR-21-208, FY2022–FY2026

Funding by fiscal year

Award records, new awards, and funding by fiscal year under PAR-21-208
Fiscal yearAward recordsNew awardsFunding
FY202222$435K
FY2023119$2.4M
FY2024145$2.9M
FY202574$2.3M
FY202600$0

Institutions with the most funding

  1. Yale University$818K · 2 projects
  2. University of Pennsylvania$454K · 1 project
  3. Stanford University$437K · 1 project

Funding institutes

  • NIDA$8.1M · 34

Activity codes funded

FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.

Participating institutes

2 NIH institutes and offices take applications under PAR-25-101. Contact the program officer at the institute that fits your research before applying.

  • NIDA · National Institute on Drug Abuse
  • none

Related notices

  1. Mar 31, 2025 · NOT-OD-24-084

    This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…

  2. Aug 31, 2022 · NOT-OD-22-198

    Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.

  3. Aug 5, 2022 · NOT-OD-22-189

    Implementation Details for the NIH Data Management and Sharing Policy.

Notices of Special Interest (NOSIs)

NIH has attached 8 NOSIs to PAR-25-101; none are active now. A NOSI flags a topic an institute wants to fund through this NOFO.

Award terms

Application types allowed
NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
Award budget
 The combined budget for direct costs for the two year project period may not exceed 275,000. No more than 150,000 in direct costs may be requested in any single year.
Project period
The maximum project period is 2 years.       NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
Funds available and number of awards
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.

Related NOFOs

  • Reissue of PAR-21-208.

Other open NOFOs for R21

Browse all open NIH NOFOs

About this page

GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.

Find who wins under this NOFO